



Count	Module Name	QOPI Measure Number	Round 2 2018: Measure Name	MOQC Notes to ASCO-QOPI
1	Core	6e	Pain addressed appropriately by 2nd office visit and during most recent office visit	
2	Core	13a1	Chemotherapy administered to patients with metastatic solid tumor with performance status of 3,4 or undocumented	Removed from MOQC Pathway for Spring/Round 1 2018
3	Core	13oc6a	Oral chemotherapy monitored on visit/contract following start of therapy: medication adherence assessed (CORE)	
4	Core	14	Signed patient consent for chemotherapy	
5	Core	22bb	Tobacco cessation counseling administered or patient referred in past year	
6	SMT	28a	Aprepitant/fosaprepitant or netupitant prescribed or administered with high emetic risk chemotherapy	
7	SMT	33	Infertility risks discussed prior to chemotherapy with patients of reproductive age	
8	EOL	38	Pain addressed appropriately	
9	EOL	41	Dyspnea addressed appropriately	
10	EOL	44	Hospice enrollment within 3 days of death	
11	EOL	47	Hospice enrollment, palliative care referral/services or documented discussion	
12	Breast	61	IV Bisphosphonates or denosumab administered for breast cancer bone mets	
13	Breast	62a1	PET, CT or radionuclide ordered by practice within 60 days after diagnosis to stage I,IIA or IIB breast cancer	
14	Breast	62c1	Serum tumor marker surveillance ordered by practice between 30-365 days after diagnosis of breast cancer in patients who received treatment with curative intent for breast cancer	
15	CRC	63	Complete family history documented for patients with invasive colorectal cancer	
16	CRC	73	Colonoscopy before or within 6 months or curative colorectal resection or completion of primary adjuvant chemotherapy	
17	NSCLC	89a	Growth colonizing stimulating factor (GCSF) administered to patients who receive chemotherapy for metastatic NSCLC	Removed from MOQC Pathway for Spring/Round 1 2018
18	EOL	48	Chemotherapy administered within the last two weeks of life	New addition to MOQC Pathway but a current QOPI Measure



Count	Module Name	QOPI Measure Number	Round 2 2018: Measure Name	MOQC Notes to ASCO-QOPI
19	Gyn-On	90g	Operative report with documentation of residual disease within 48 hours of cytoreduction for women with invasive ovarian, fallopian tube or peritoneal cancer	New addition to MOQC Pathway but a current QOPI Measure
20	Gyn-On	94	Platin or taxane administered within 42 days following cytoreduction to women with invasive Stage I (grade 3), IC-IV ovarian, fallopian tube, or primary peritoneal cancer	New addition to MOQC Pathway but a current QOPI Measure
			*Note: For MOQC Pathway, change "within 42 days" to "within 28 days" for Measure 94	
21	Gyn-On	MOQC Gyn-Onc #1*	Days from debulking surgery to chemotherapy start	New test measure for QOPI and for MOQC Pathway
22	Gyn-On	MOQC Gyn-Onc #2*	Patients with ovarian cancer referred for genetic testing/counselling	New test measure for QOPI and for MOQC Pathway